To address this gap, the Assessing the Dosage Pattern and Demographic Characteristics in Heart Failure Reduced Ejection Fraction Patients Initiated with Angiotensin Receptor-Neprilysin Inhibitor in India (ADD-ARNI) study is a first-of-its-kind prospective, multicenter observational study designed to evaluate the dosage patterns and treatment persistence of ARNI therapy in patients with HFrEF in India. The gene discussed is MME; the disease is heart failure.